CLPT · ClearPoint Neuro, Inc.
$12.21
+0.44 (+3.74%)
At close · Sep 30
Return incl. dividend (before tax)
Market Cap
$362.24M
Shares
30.50M
Volume · Sep 30
1.25M
Avg daily vol (3M)
618.1K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$12.21
Open$11.85
Day$11.54–12.54
52W close$8.66–29.60
Avg vol 30d670K
Short int4.3M · 14.2% float · 6.9d
Short vol53%
Last earningsAug 3, 2026
DataJan 2020–Sep 2026
Filing10-Q · Aug 3
Up next
Next earnings call
Oct 26, 2026
Est · unconfirmed
· in 4 wks
filed Aug 3, 2026
call held Aug 3, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
-44.0%
Trailing year
Short interest
14.2%
Latest settlement · 6.9 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Neutral
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 16.3 · calm
Equity put/call 0.53
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−9%
below
Price vs 50-day avg
−16%
below
RSI (14)
38
neutral
MACD trend
Negative
52-week position
17%
mid-range
Momentum
relative strength
1-month return
−18%
trailing
6-month return
+36%
trailing
YTD return
−11%
this year
Relative strength
+24%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $15 › 200d $13 — 50d above 200d
Institutional flow
Accumulating
+7% holders QoQ · +21 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
14.19% of float · ▲ +3.3% MoM · 6.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
130 holders — near 3-yr high, broad support
Squeeze score
63
elevated · 0–100
Fundamentals
Revenue growth
+18%
Y/Y
Gross margin
61%
expanding
EPS growth
−29%
Y/Y
Free cash flow
$-24.4M
Balance sheet
$3.2M
net debt
Quant / Vol
risk profile
Volatility
91%
annualized · 1-yr
Max drawdown
−71%
past year
ATR
8.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 3, 2026
Revenue
· 2026
$48M – $52M
prior FY $36.97M
midpoint +35.2% Y/Y
Guided vs delivered
· last 6 settled
Revenue
2024
guided $28M – $32M
$31.39M
In line
Total revenue
2023
guided $23M – $25M
$23.96M
In line
Revenue
full year 2022
guided $20M – $22M
$20.55M
In line
Full year 2021 revenue
full year 2021
guided $16M – $17.5M
$16.3M
In line
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−9%
Bearish
Price vs 50-day avg
−16%
Bearish
RSI (14)
38
Neutral
MACD trend
Negative
Bearish
52-week position
17%
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $15 › 200d $13 — 50d above 200d
Institutional flow
Accumulating
+7% holders QoQ · +21 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
14.19% of float · ▲ +3.3% MoM · 6.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
130 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $9
Now $12 · 17%
Range high $30
vs 200-day avg -9%
vs 50-day avg -16%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CLPT
this stock
ClearPoint Neuro, Inc.
|
$362.24M | -10.7% | +17.8% | — | 14.2% |
|
ABT
Abbott Laboratories
|
$174.90B | -21.1% | +5.7% | 28.1 | 1.1% |
|
MDT
Medtronic plc
|
$113.38B | -10.2% | +8.4% | 21.8 | 1.3% |
|
SYK
Stryker Corp
|
$104.47B | -21.6% | +11.2% | 28.2 | 2.0% |
|
BSX
Boston Scientific Corp
|
$63.59B | -54.2% | +12.5% | 17.8 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CLPT | -18.4% | -18.1% | +36.3% | -19.4% | -10.8% |
| SPY | -0.7% | +0.1% | +12.2% | -0.6% | +11.8% |
| vs SPY | -17.8% | -18.2% | +24.1% | -18.8% | -22.6% |